High moxifloxacin cross-resistance levels among “newly identified” ofloxacin-resistant multidrug-resistant tuberculosis patients from South India: A ticking bomb or a tricky challenge?

Sanker, Praveen; Satheesan, Anjana; Ambika, Anusree P; Santhosh, Vishnu T; Balakrishnan, Ravikrishnan; Mrithunjayan, Sunil Kumar

doi:10.4103/bbrj.bbrj_7_17

Cited by 4 publications

(12 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In National Anti-Tuberculosis Drug Resistance Survey, additional resistance to FQ, among MDR-TB patients was shown to be 21.82 % 2,5 . Association of FQ resistance among individuals with resistance to first-line TB drugs is evidence of acquired FQ resistance while on treatment for TB 3 . In the current study, additional resistance to FQ , among MDR-TB patients was seen in 14.2% patients and was lower.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…I n fe c t i o n w i t h M y c o b a c t e r i u m tuberculosis resistant to isoniazid (H) and rifampicin (R) also called as MDR-TB or RR TB, [1][2][3] leads to treatment with less potent, more toxic and expensive second-line anti-TB drugs (SLD). Fluoroquinolones (FQ) are crucial and integral part of drug resistant tuberculosis (DR-TB) treatment regimens 1,3,4 . Wide and illogic use of FQ, either for tuberculosis (TB) or other infections of respiratory tract, is responsible for increasing FQ resistance in MDR-TB, and lead to a situation where treatment options are narrowed 1,3 .…”

Section: Introductionmentioning

confidence: 99%

“…Fluoroquinolones (FQ) are crucial and integral part of drug resistant tuberculosis (DR-TB) treatment regimens 1,3,4 . Wide and illogic use of FQ, either for tuberculosis (TB) or other infections of respiratory tract, is responsible for increasing FQ resistance in MDR-TB, and lead to a situation where treatment options are narrowed 1,3 . FQ resistance and poor treatment outcomes in MDR-TB have been reported in studies 4,5 .…”

Section: Introductionmentioning

confidence: 99%

“…FQ resistance may thus be a more prevalent than actually reported and can threaten TB control programmes 1 . Studies from India have demonstrated the prevalence of FQ resistance in MDR-TB patients 1,3,7,8,9 but none from North Coastal Andhra Pradesh. Hence we studied the proportion of FQ resistance among MDR-TB/RR-TB and also the proportion of their cross-resistance among MDR-TB/RR-TB isolates.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Additional Resistance to any Fluoroquinolones among Multidrug-resistant Mycobacterium tuberculosis Isolates from North Coastal Andhra Pradesh, India

Suresh¹,

Vimala²,

Mohan³

et al. 2021

J Pure Appl Microbiol

View full text Add to dashboard Cite

Fluoroquinolones (FQ) are integral part of multidrug resistant/rifampicin resistant tuberculosis (MDR-TB/RR TB) treatment regimens. FQ resistance in MDR-TB lead to narrower treatment options and poor treatment outcomes. Hence proportion of FQ resistance among MDR-TB and cross-resistance among FQ in MDR-TB isolates was studied. This is the first study from North Coastal Andhra Pradesh, India. A cross-sectional study was conducted on 21,474 sputum samples from January-December 2018 & 833 culture isolates (rifampicin resistant detected by GeneXpert MTB / RIF assay & MDR-TB detected by direct and indirect GenoType MTBDRplus Assay) were analysed for FQ resistance by Mycobacterium Growth Indicator Tube (MGIT) for ofloxacin (Ofx) 2.0 µg/mL, levofloxacin (Lfx) 1.5 µg/mL & moxifloxacin (Mfx) 2.0 μg/mL. Among 833 culture isolates, 119 (14.2%) showed resistance to FQ which included 90 (10.8%) Ofx and Lfx resistance isolates but still sensitive to Mfx, 16 (1.92%) with resistance to all FQ tested, 12 Ofx monoresistance & 1 Lfx monoresistance. Mfx monoresistance was absent. Mfx sensitive isolates are 714 (85.7%) and were always sensitive to Ofx and Lfx. Cross-resistance was not complete. MDR-TB/RR TB is 4.1% among all TB patients. Additional resistance to FQ, among MDR-TB patients was seen in 14.2% patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Additional Resistance to any Fluoroquinolones among Multidrug-resistant Mycobacterium tuberculosis Isolates from North Coastal Andhra Pradesh, India

Suresh¹,

Vimala²,

Mohan³

et al. 2021

J Pure Appl Microbiol

View full text Add to dashboard Cite

show abstract

Newly registered tuberculosis: A comparison of rate and success of management in two island districts with different in accessibility of transportation in Thailand

Yasri¹,

Wiwanitkit

2019

Int J Mycobacteriol

View full text Add to dashboard Cite

Prevalence and Temporal Trends of Multidrug-resistant Tuberculosis in Iran from 1981 to 2023: A Systematic Review and Meta-analysis

Ayoubi,

Farnia,

Farnia

et al. 2024

The International Journal of Mycobacteriology

View full text Add to dashboard Cite

Background: Multidrug-resistant tuberculosis (MDR-TB) is a serious threat to global tuberculosis (TB) control efforts. This study aims to investigate the trend of MDR-TB prevalence in Iran over 20 years. Methods: A systematic literature search was conducted in various databases, including PubMed, Embase, and Web of Science, from 1981 to 2023. Studies reporting the prevalence of MDR-TB in Iran were included in the meta-analysis. Statistical analysis was performed using Comprehensive Meta-Analysis software. Results: A total of 58 studies from different provinces of Iran were included in the meta-analysis. The majority of studies were from Tehran (n = 33), Kermanshah (n = 5), Mashhad (n = 4), and Tabriz (n = 4) provinces. Overall, 1885 cases of MDR-TB were reported in Iran during the study period. The highest number of MDR-TB cases was reported in 2000 (582 cases) and the lowest in 2001 (1 case). An increasing trend in MDR-TB prevalence was observed, particularly between 2018 and 2019. The pooled prevalence of MDR-TB in Iran was 12.31% (95% CI: 11.83–12.80) using the fixed-effects model and 20.21% (95% CI: 15.70–26.01) using the random-effects model. No evidence of publication bias was found. Conclusion: The results of this comprehensive meta-analysis highlight the increasing trend of MDR-TB in Iran over the past two decades. This underscores the urgent need for strengthening TB control strategies, including improved surveillance, case detection, treatment, and management of MDR-TB in the country. Developing diagnostic and treatment approaches for MDR-TB should be prioritized by Iranian medical universities and public health authorities.

show abstract

High moxifloxacin cross-resistance levels among “newly identified” ofloxacin-resistant multidrug-resistant tuberculosis patients from South India: A ticking bomb or a tricky challenge?

Cited by 4 publications

References 1 publication

Additional Resistance to any Fluoroquinolones among Multidrug-resistant Mycobacterium tuberculosis Isolates from North Coastal Andhra Pradesh, India

Additional Resistance to any Fluoroquinolones among Multidrug-resistant Mycobacterium tuberculosis Isolates from North Coastal Andhra Pradesh, India

Newly registered tuberculosis: A comparison of rate and success of management in two island districts with different in accessibility of transportation in Thailand

Prevalence and Temporal Trends of Multidrug-resistant Tuberculosis in Iran from 1981 to 2023: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About